Glenmark Pharmaceuticals Limited – NSE:GLENMARK.NS

Glenmark Pharmaceuticals Limited stock price today

INR 525.25
-1060.7
-66.88%
Financial Health
0
1
2
3
4
5
6
7
8
9

Glenmark Pharmaceuticals Limited stock price monthly change

+14.80%
month

Glenmark Pharmaceuticals Limited stock price quarterly change

+14.80%
quarter

Glenmark Pharmaceuticals Limited stock price yearly change

+87.45%
year

Glenmark Pharmaceuticals Limited key metrics

Market Cap
 437.56B
Enterprise value
 447.15B
P/E
 -51.14
EV/Sales
 3.67
EV/EBITDA
 24.14
Price/Sales
 3.67
Price/Book
 5.30
PEG ratio
 124.33
EPS
 -53.21
Revenue
 120.20B
EBITDA
 14.57B
Income
 -15.01B
Revenue Q/Q
 -7.20%
Revenue Y/Y
 -5.54%
Profit margin
 -7.19%
Oper. margin
 4.22%
Gross margin
 51.61%
EBIT margin
 4.22%
EBITDA margin
 12.12%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Glenmark Pharmaceuticals Limited stock price history

Glenmark Pharmaceuticals Limited stock forecast

Glenmark Pharmaceuticals Limited financial statements

Profit Margin

Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Profit margin
Jun 2023 33.36B 1.49B 4.49%
Sep 2023 31.60B -819.45M -2.59%
Dec 2023 24.60B -3.51B -14.28%
Mar 2024 30.62B -12.18B -39.77%
GLENMARK.NS income statement history

Glenmark Pharmaceuticals Limited Financials Estimate

Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Analyst Estimates
2026 153.62B 16.31B 10.62%
2027 174.74B 21.35B 12.22%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Quarterly Earnings

Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Earnings per share (EPS)
2023-02-13 7.93 9.66
GLENMARK.NS earnings history
0.15%
Yield TTM
Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Payout ratio
Payout ratio 0%
Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Dividend Yield
2016 0.3%
2017 0.28%
2019 0.37%
2020 1.18%
2022 0.74%
GLENMARK.NS dividends history

Debt to Assets

Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Debt to assets
Jun 2023 0 0
Sep 2023 200064160000 102.70B 51.34%
Dec 2023 0 0
Mar 2024 143586240000 65.11B 45.35%
GLENMARK.NS balance sheet history

Cash Flow

Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Cash Flow
Jun 2023 3.09B 0 0
Sep 2023 2.82B 0 0
Dec 2023 2.94B 0 0
Mar 2024 0 0 0
GLENMARK.NS cash flow history

Glenmark Pharmaceuticals Limited alternative data

Glenmark Pharmaceuticals Limited
Employees

Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS): Employee count
Aug 2023 15,415
Sep 2023 15,415
Oct 2023 15,556
Nov 2023 15,556
Dec 2023 15,556
Jan 2024 15,556
Feb 2024 15,556
Mar 2024 15,556
Apr 2024 15,556
May 2024 15,556
Jun 2024 15,556
Jul 2024 15,556

Glenmark Pharmaceuticals Limited other data

Glenmark Pharmaceuticals Limited
Executives

Insider Compensation
Mr. Glenn Mario Saldanha (1970) Chairman, MD & Chief Executive Officer
 $138,570,000
Mr. V. S. Mani (1965) Global Chief Financial Officer & Executive Director
 $62,260,000
Ms. Cherylann Maria Pinto (1967) Executive Director of Corporation Services & Executive Director
 $40,700,000

Frequently Asked Questions (FAQ)

  • What's the price of Glenmark Pharmaceuticals Limited stock today?

    One share of Glenmark Pharmaceuticals Limited stock can currently be purchased for approximately $525.25.

  • When is Glenmark Pharmaceuticals Limited's next earnings date?

    Unfortunately, Glenmark Pharmaceuticals Limited's (GLENMARK.NS) next earnings date is currently unknown.

  • Does Glenmark Pharmaceuticals Limited pay dividends?

    Yes, Glenmark Pharmaceuticals Limited pays dividends and its trailing 12-month yield is 0.16% with 0% payout ratio. The last Glenmark Pharmaceuticals Limited stock dividend of $0 was paid on 12 Sep 2025.

  • How much money does Glenmark Pharmaceuticals Limited make?

    Glenmark Pharmaceuticals Limited has a market capitalization of 437.56B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 2.97% to 118.13B US dollars. Glenmark Pharmaceuticals Limited made a loss 15.02B US dollars in net income (profit) last year or $9.66 on an earnings per share basis.

  • What is Glenmark Pharmaceuticals Limited's stock symbol?

    Glenmark Pharmaceuticals Limited is traded on the NSE under the ticker symbol "GLENMARK.NS".

  • What is Glenmark Pharmaceuticals Limited's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Glenmark Pharmaceuticals Limited?

    Shares of Glenmark Pharmaceuticals Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Glenmark Pharmaceuticals Limited's key executives?

    Glenmark Pharmaceuticals Limited's management team includes the following people:

    • Mr. Glenn Mario Saldanha Chairman, MD & Chief Executive Officer(age: 55, pay: $138,570,000)
    • Mr. V. S. Mani Global Chief Financial Officer & Executive Director(age: 60, pay: $62,260,000)
    • Ms. Cherylann Maria Pinto Executive Director of Corporation Services & Executive Director(age: 58, pay: $40,700,000)

  • How many employees does Glenmark Pharmaceuticals Limited have?

    As Jul 2024, Glenmark Pharmaceuticals Limited employs 15,556 workers.

  • When Glenmark Pharmaceuticals Limited went public?

    Glenmark Pharmaceuticals Limited is publicly traded company for more then 23 years since IPO on 1 Jul 2002.

  • What is Glenmark Pharmaceuticals Limited's official website?

    The official website for Glenmark Pharmaceuticals Limited is glenmarkpharma.com.

  • How can i contact Glenmark Pharmaceuticals Limited?

    Glenmark Pharmaceuticals Limited can be reached via phone at +91 22 4018 9999.

Glenmark Pharmaceuticals Limited company profile:

Glenmark Pharmaceuticals Limited

glenmarkpharma.com
Exchange:

NSE

Full time employees:

14,989

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

+91 22 4018 9999
Glenmark House
Mumbai, 400099

:
ISIN: INE935A01035
CUSIP: Y2711C144